A. Kerber

838 total citations
28 papers, 536 citations indexed

About

A. Kerber is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, A. Kerber has authored 28 papers receiving a total of 536 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 8 papers in Radiology, Nuclear Medicine and Imaging and 7 papers in Immunology. Recurrent topics in A. Kerber's work include CAR-T cell therapy research (7 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). A. Kerber is often cited by papers focused on CAR-T cell therapy research (7 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). A. Kerber collaborates with scholars based in Germany, France and United States. A. Kerber's co-authors include Jörg Reichrath, Friedrich A. Bahmer, Hans‐Peter Baum, Michael F. Holick, Ralf Paus, Wolfgang Tilgen, Beate M. Czarnetzki, Simon Müller, Tai C. Chen and Joachim von Pawel and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Cancer.

In The Last Decade

A. Kerber

28 papers receiving 520 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Kerber Germany 13 187 155 132 128 122 28 536
Masahito Yasuda Japan 14 134 0.7× 144 0.9× 79 0.6× 95 0.7× 128 1.0× 50 536
Thomas Pap Switzerland 6 144 0.8× 246 1.6× 191 1.4× 137 1.1× 45 0.4× 7 689
Takenao Chino Japan 9 62 0.3× 166 1.1× 72 0.5× 86 0.7× 45 0.4× 21 496
Arja Jukkola‐Vuorinen Finland 15 202 1.1× 196 1.3× 71 0.5× 43 0.3× 38 0.3× 40 687
Daichi Hoshina Japan 13 75 0.4× 107 0.7× 61 0.5× 74 0.6× 112 0.9× 25 397
Dagmar Foedinger Austria 13 135 0.7× 122 0.8× 56 0.4× 283 2.2× 54 0.4× 23 573
Cheng‐Cheng Deng China 9 79 0.4× 219 1.4× 76 0.6× 41 0.3× 165 1.4× 20 501
Jon M. Carthy Canada 12 102 0.5× 296 1.9× 39 0.3× 40 0.3× 22 0.2× 20 598
Wenchang Lv China 16 139 0.7× 546 3.5× 113 0.9× 42 0.3× 132 1.1× 34 869
B. McLaughlin United Kingdom 10 87 0.5× 158 1.0× 114 0.9× 28 0.2× 31 0.3× 16 342

Countries citing papers authored by A. Kerber

Since Specialization
Citations

This map shows the geographic impact of A. Kerber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Kerber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Kerber more than expected).

Fields of papers citing papers by A. Kerber

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Kerber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Kerber. The network helps show where A. Kerber may publish in the future.

Co-authorship network of co-authors of A. Kerber

This figure shows the co-authorship network connecting the top 25 collaborators of A. Kerber. A scholar is included among the top collaborators of A. Kerber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Kerber. A. Kerber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nair, Ranjit, Faustine Lhomme, Anthony Le Bras, et al.. (2020). Acute leucoencephalomyelopathy and quadriparesis after CAR T-cell therapy. Haematologica. 106(5). 1504–1506. 25 indexed citations
2.
Topp, Max S., Tom van Meerten, Roch Houot, et al.. (2019). Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma. Blood. 134(Supplement_1). 243–243. 42 indexed citations
3.
Topp, Max S., Tom van Meerten, Martin Wermke, et al.. (2019). PS1067 AXICABTAGENE CILOLEUCEL (AXI‐CEL) IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA: PRELIMINARY RESULTS OF EARLIER STEROID USE. HemaSphere. 3(S1). 483–483. 1 indexed citations
4.
Gantke, Thorsten, Uwe Reusch, Christian Kellner, et al.. (2017). AFM26 - Targeting B Cell Maturation Antigen (BCMA) for NK Cell-Mediated Immunotherapy of Multiple Myeloma. Blood. 130. 3082–3082. 6 indexed citations
5.
Kerber, A., Michael Kluge, Uwe Reusch, et al.. (2017). EGFR/CD16A tetravalent bispecific antibody AFM24 to engage NK-cells to kill EGFR expressing tumor cells and safety results in cynomolgus monkey studies.. Journal of Clinical Oncology. 35(15_suppl). e14001–e14001. 3 indexed citations
6.
Pahl, Jens, Uwe Reusch, Thorsten Gantke, et al.. (2016). AFM13 Is the Most Advanced Bispecific NK-Cell Engaging Antibody in Clinical Development Substantially Enhancing NK-Cell Effector Function and Proliferation. Blood. 128(22). 1764–1764. 2 indexed citations
7.
Manegold, Christian, Johan Vansteenkiste, Felipe Cardenal, et al.. (2012). Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer. Investigational New Drugs. 31(1). 175–182. 52 indexed citations
8.
Vermorken, Jan B., J. Guigay, Ricard Mesı́a, et al.. (2011). Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part. British Journal of Cancer. 104(11). 1691–1696. 45 indexed citations
9.
Al-Batran, S-E., A. Kerber, Hans-Joachim Lueck, et al.. (2008). Interim safety analysis of a randomized phase III study evaluating pegylated liposomal doxorubicin (PLD) versus capecitabine as first line chemotherapy for metastatic breast cancer (MBC) – The PELICAN study. European Journal of Cancer Supplements. 6(7). 177–177. 3 indexed citations
10.
Al‐Batran, Salah‐Eddin, A. Kerber, Akin Atmaca, et al.. (2007). Mitomycin C, 5-Fluorouracil, Leucovorin, and Oxaliplatin as a Salvage Therapy for Patients with Cisplatin-Resistant Advanced Gastric Cancer: A Phase I Dose Escalation Trial. Oncology Research and Treatment. 30(1-2). 29–34. 10 indexed citations
11.
Reichrath, Jörg, et al.. (2006). Hair follicle expression of 1,25-dihydroxyvitamin D3 receptors during the murine hair cycle. British Journal of Dermatology. 131(4). 477–482. 41 indexed citations
12.
Ladewig, Gesa, Uwe Reinhold, Charles E. Thirkill, et al.. (2005). Incidence of antiretinal antibodies in melanoma: screening of 77 serum samples from 51 patients with American Joint Committee on Cancer stage I-IV. British Journal of Dermatology. 152(5). 931–938. 26 indexed citations
13.
Kerber, A., et al.. (2004). The new DR‐70 immunoassay detects cancer of the gastrointestinal tract: a validation study. Alimentary Pharmacology & Therapeutics. 20(9). 983–987. 24 indexed citations
14.
Kerber, A., et al.. (2003). 44-j�hrige Patientin mit fulminantem Leberversagen. Der Internist. 44(10). 1301–1307. 1 indexed citations
15.
Kerber, A.. (2000). Paraneoplastische Hypoglykämie beim lokalisierten fibrösen Tumor der Pleura. Der Chirurg. 71(12). 1484–1488. 1 indexed citations
16.
Reichrath, Jörg, et al.. (2000). Immunoreactivity of Six Monoclonal Antibodies Directed Against 1,25-dihydroxyvitamin-D3 Receptors in Human Skin. The Histochemical Journal. 32(10). 625–629. 17 indexed citations
17.
Reichrath, Jörg, et al.. (1997). Biologic effects of topical calcipotriol (MC 903) treatment in psoriatic skin. Journal of the American Academy of Dermatology. 36(1). 19–28. 90 indexed citations
18.
Reichrath, Jörg, Simon Müller, Tai C. Chen, et al.. (1997). Topical calcitriol (1,25-dihydroxyvitamin D3) treatment of psoriasis: an immunohistological evaluation.. Acta Dermato Venereologica. 77(4). 268–272. 49 indexed citations
19.
Reichrath, Jörg, et al.. (1996). Immunohistochemical Detection of 1,25-dihydroxyvitamin D3 Receptors (VDR) in Human Skin. Pathology - Research and Practice. 192(3). 281–289. 27 indexed citations
20.
Reichrath, Jörg, et al.. (1995). In situ detection of retinoid-X receptor expression in normal and psoriatic human skin. British Journal of Dermatology. 133(2). 168–175. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Masahito Yasuda Breakdown of academic impact, for papers by Thomas Pap Breakdown of academic impact, for papers by Takenao Chino Breakdown of academic impact, for papers by Arja Jukkola‐Vuorinen Breakdown of academic impact, for papers by Daichi Hoshina Breakdown of academic impact, for papers by Dagmar Foedinger Breakdown of academic impact, for papers by Cheng‐Cheng Deng Breakdown of academic impact, for papers by Jon M. Carthy Breakdown of academic impact, for papers by Wenchang Lv Breakdown of academic impact, for papers by B. McLaughlin
Rankless by CCL
2026